ONCT — Oncternal Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
Brief: Oncternal Reports Third Quarter 2021 Financial Results
Brief: Oncternal Therapeutics Reports Formation Of Cell Therapy Scientific Advisory Board
Oncternal Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Oncternal Therapeutics Announced Pre-Clinical Data From Onct-534, An Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader
Brief: Oncternal Therapeutics And Celularity Enter Into Research Collaboration To Evaluate Targeted Placental-Derived Cellular Therapies
Brief: Celularity Says Co And Oncternal Therapeutics Enter Into Research Collaboration To Evaluate Targeted Placental-Derived Cellular Therapies
Oncternal Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Oncternal Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Oncternal Therapeutics Appoints Pablo Urbaneja As Sr. Vice President, Corporate Development
Brief: Oncternal Therapeutics Enters Into Agreement With Jefferies Pursuant To Which Co May Offer & Sell Shares Of Co's Common Stock Of Up To $50 Million
U.S. STOCKS ON THE MOVE-Tesla, VBI Vaccines, Ralph Lauren, Virgin Galactic
U.S. STOCKS ON THE MOVE-Riot Blockchain, Kohl's, Ralph Lauren, PDS Biotech
U.S. STOCKS ON THE MOVE-KE Holdings, Advaxis, DoorDash, Virgin Galactic
Oncternal Therapeutics: Jumps on positive data from rare cancer study
Brief: Oncternal Therapeutics Announces Appointment Of Salim Yazji As Chief Medical Officer
Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Oncternal Provides Business Update And Announces First Quarter 2021 Financial Results
Brief: Oncternal Therapeutics Inc Files For Mixed Shelf Of Up To $250 Mln
Brief: Oncternal Therapeutics Inc Posts Q4 Loss Per Share $0.09